









Markets
/
Stocks
/
nasdaq-iqv
/

IQVIA Holdings Inc

IQV



View Detailed Chart

187.220USD

-3.500-1.84%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

31.83BMarket Cap

25.73P/E TTM



IQVIA Holdings Inc

187.220

-3.500-1.84%

Overview Company Financials Analysis

Analysis

Intraday

30m

Today

-1.84%

5 Days

-0.25%

1 Month

-1.58%

6 Months

+3.19%

Year to Date

-4.73%

1 Year

-21.57%

View Detailed Chart

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

24 / 507

Overall Ranking

146 / 4724

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 25 analysts

Buy

Current Rating

215.812

Target Price

+15.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

IQVIA Holdings Inc. is a provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Its segments include Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Technology & Analytics Solutions segment offers mission-critical information, technology solutions and real-world insights and services to its life science clients. Research & Development Solutions segment serves biopharmaceutical customers and provides outsourced clinical research and clinical trial related services. Contract Sales & Medical Solutions segment offers health care providers (including contract sales) and patient engagement services to both biopharmaceutical clients and the broader healthcare market. Its Connected Intelligence delivers insights and solutions enabling customers to accelerate the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 15.40B.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 25.85.

Overvalued

The company’s latest PE is 26.90, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 166.70M shares, decreasing 5.37% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 19.60M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.10.